Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke
NCT05953623Phase 1Completed
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Aug 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of albumin (human) in ischemic stroke, sponsored by Tianjin Huanhu Hospital. Primary endpoint: All cause of death at 90 days. Started Aug 2023; status: completed.
02
Drugs
albumin (human)
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05953623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953623.